Invasive fungal infections (IFIs) are associated with considerable morbidity and mortality in critically ill patients, with invasive candidiasis and invasive aspergillosis as the most prevalent IFIs affecting non-neutropenic patients in intensive care units. It is therefore imperative for clinicians to maintain vigilance in identifying risk factors, especially among hospitalized and immunocompromised individuals. The existing antifungal therapeutic options are limited and hampered by drug-drug interactions, toxicity, and constraints in administration routes. However, novel therapeutic approaches are being developed and their characteristics and optimal utilization could positively impact patient outcomes.
Medscape Education© WebMD Global, LLC